JP7664855B2 - 乳がんを処置するためのリュープロリド酢酸塩組成物およびその使用方法 - Google Patents

乳がんを処置するためのリュープロリド酢酸塩組成物およびその使用方法 Download PDF

Info

Publication number
JP7664855B2
JP7664855B2 JP2021569057A JP2021569057A JP7664855B2 JP 7664855 B2 JP7664855 B2 JP 7664855B2 JP 2021569057 A JP2021569057 A JP 2021569057A JP 2021569057 A JP2021569057 A JP 2021569057A JP 7664855 B2 JP7664855 B2 JP 7664855B2
Authority
JP
Japan
Prior art keywords
leuprolide
extended release
subject
release composition
lactide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021569057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535694A5 (enExample
JP2022535694A (ja
Inventor
ジョン ミドルトン，
アビナッシュ ナンギア，
ジョン アーサー マクレーン，
テリー エル． モートン，
Original Assignee
トルマー インターナショナル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トルマー インターナショナル リミテッド filed Critical トルマー インターナショナル リミテッド
Publication of JP2022535694A publication Critical patent/JP2022535694A/ja
Publication of JP2022535694A5 publication Critical patent/JP2022535694A5/ja
Application granted granted Critical
Publication of JP7664855B2 publication Critical patent/JP7664855B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2021569057A 2019-05-27 2020-05-26 乳がんを処置するためのリュープロリド酢酸塩組成物およびその使用方法 Active JP7664855B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27
US62/853,153 2019-05-27
PCT/IB2020/054984 WO2020240417A1 (en) 2019-05-27 2020-05-26 Leuprolide acetate compositions and methods of using the same to treat breast cancer

Publications (3)

Publication Number Publication Date
JP2022535694A JP2022535694A (ja) 2022-08-10
JP2022535694A5 JP2022535694A5 (enExample) 2023-06-05
JP7664855B2 true JP7664855B2 (ja) 2025-04-18

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569057A Active JP7664855B2 (ja) 2019-05-27 2020-05-26 乳がんを処置するためのリュープロリド酢酸塩組成物およびその使用方法

Country Status (17)

Country Link
US (2) US12453754B2 (enExample)
EP (1) EP3975990A1 (enExample)
JP (1) JP7664855B2 (enExample)
KR (1) KR20220041782A (enExample)
CN (1) CN114144169A (enExample)
AR (1) AR119021A1 (enExample)
AU (1) AU2020284587B2 (enExample)
BR (1) BR112021023904A2 (enExample)
CA (1) CA3141456A1 (enExample)
EA (1) EA202193257A1 (enExample)
IL (1) IL288503A (enExample)
MX (1) MX2021014540A (enExample)
PH (1) PH12021552976A1 (enExample)
SG (1) SG11202112888RA (enExample)
TW (1) TWI757753B (enExample)
UY (1) UY38717A (enExample)
WO (1) WO2020240417A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144169A (zh) 2019-05-27 2022-03-04 托尔玛国际有限公司 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法
DK4135830T3 (da) 2020-12-23 2024-10-28 Tolmar International Ltd Systemer og fremgangsmåder til blanding af sprøjteventilanordninger
CN115518144A (zh) * 2021-06-26 2022-12-27 王婧宜 一种含有亮丙瑞林或其衍生物的口服药物组合物
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523798A (ja) 2006-01-18 2009-06-25 キューピーエス リミテッド ライアビリティ カンパニー 高い安定性を持つ薬理組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
JP4259610B2 (ja) 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
DK3660073T3 (da) * 2007-02-15 2023-09-18 Tolmar International Ltd Poly(lactid-co-glycolid) med lav sprængning
DE202009010095U1 (de) 2009-07-24 2009-10-22 Chang, Ti-Li, Houli Verbindungsvorrichtung für einen auswechselbaren, abgeschlossenen Sekret-Absaugkatheter
IL301603A (en) * 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
CN114144169A (zh) 2019-05-27 2022-03-04 托尔玛国际有限公司 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法
KR102162217B1 (ko) 2020-05-07 2020-10-06 주식회사 파인비엠 스태틱믹서를 갖는 연결장치를 구비한 시린지 결합 키트
DK4135830T3 (da) 2020-12-23 2024-10-28 Tolmar International Ltd Systemer og fremgangsmåder til blanding af sprøjteventilanordninger
AU2022331238A1 (en) 2021-08-19 2024-02-01 Carefusion 303, Inc. Pivc-integrated hemolysis-reduction accessories with anti-spillage component for direct blood draw
FR3131618A1 (fr) 2021-12-30 2023-07-07 Parker Hannifin Emea Sarl Dispositif de raccordement aseptique d’un tube

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523798A (ja) 2006-01-18 2009-06-25 キューピーエス リミテッド ライアビリティ カンパニー 高い安定性を持つ薬理組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KIM, H.J. et al.，Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea，European Journal of Surgical Oncology (EJSO)，2009年，Volume 35, Issue 9，<DOI: 10.1016/j.ejso.2009.01.016>
KUREBAYASHI, J. et al.，Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study，Breast Cancer，2017年，Volume 24, pages 161-170，<DOI: 10.1007/s12282-016-0691-6>
KUREBAYASHI, J. et al.，Hormone dynamics, pharmacokinetics, safety and efficacy of leuprorelin acetate 6-month depot formulation and tamoxifen adjuvant endocrine therapy combination in premenopausal patients with hormone receptor-positive breast cancer, [abstract]，Cancer Res，2016年，76(4 Suppl):Abstract nr P5-12-07，<DOI: 10.1158/1538-7445.SABCS15-P5-12-07>
RAVIVARAPU, H.B. et al.，Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant，AAPS PharmSciTech.，2000年，1(1), article 1，<DOI: 10.1208/pt010101>
RAVIVARAPU, H.B. et al.，Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate，J Pharm Sci.，2000年，89(6):732-41，<DOI: 10.1002/(SICI)1520-6017(200006)89:6<732::AID-JPS4>3.0.CO;2-D>
SCHMID, Peter et al.，JOURNAL OF CLINICAL ONCOLOGY，Leuprorelin Acetate Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and Fluorouracil As Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: The TABLE Study，2007年，VOLUME 25, NUMBER 18，pp. 2509-2515

Also Published As

Publication number Publication date
WO2020240417A1 (en) 2020-12-03
KR20220041782A (ko) 2022-04-01
MX2021014540A (es) 2022-04-12
AR119021A1 (es) 2021-11-17
TW202110472A (zh) 2021-03-16
IL288503A (en) 2022-01-01
TWI757753B (zh) 2022-03-11
SG11202112888RA (en) 2021-12-30
AU2020284587A1 (en) 2022-01-06
UY38717A (es) 2020-11-30
US12453754B2 (en) 2025-10-28
EA202193257A1 (ru) 2022-03-10
PH12021552976A1 (en) 2022-07-04
AU2020284587B2 (en) 2025-09-18
BR112021023904A2 (pt) 2022-02-01
US20220265760A1 (en) 2022-08-25
US20260027176A1 (en) 2026-01-29
JP2022535694A (ja) 2022-08-10
EP3975990A1 (en) 2022-04-06
CA3141456A1 (en) 2020-12-03
CN114144169A (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
US20260027176A1 (en) Leuprolide acetate compositions and methods of using the same to treat breast cancer
JP6769687B1 (ja) 皮下ｈｅｒ２抗体製剤
EP3076972B1 (en) Cancer treatment with combination of plinabulin and taxane
US20210077625A1 (en) Ray tracing technique for wireless channel measurements
JP2024519172A (ja) 進行固形腫瘍を治療する薬物の製造のためのミトキサントロン塩酸塩リポソームの用途
EA046538B1 (ru) Применение лейпролида для подавления функции яичников у субъекта с гормон-рецептор-положительным раком молочной железы
EP3793525A1 (en) Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions
MD3746047T2 (ro) Compoziție injectabilă
US20190125778A1 (en) Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
CN120361228B (zh) 一种葡萄糖激酶激活剂与pi3k抑制剂的组合物
JP4020256B2 (ja) 前立腺癌の局所治療剤
Berg et al. Therapeutic options for treating advanced colorectal cancer.
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane
Baba et al. Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients
NZ754848B2 (en) Subcutaneous her2 antibody formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250408

R150 Certificate of patent or registration of utility model

Ref document number: 7664855

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150